An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

October 20, 2015

Primary Completion Date

May 9, 2017

Study Completion Date

May 9, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Human regular U-500 insulin (CSII)

Administered SC

DRUG

Human regular U-500 insulin (MDI)

Administered SC

Trial Locations (57)

11040

North Shore Diabetes and Endocrine Assoc, New Hyde Park

15224

Partners in Nephrology & Endocrinology, Pittsburgh

19114

Endocrine Metabolic Associates, P.C., Philadelphia

27804

PMG Research of Rocky Mount, LLC, Rocky Mount

27834

Physicians East, Greenville

28803

Mountain Diabetes and Endocrine Center, Asheville

31210

East Coast Institute For Research, LLC, Macon

32216

East Coast Institute For Research, LLC, Jacksonville

33024

ALL Medical Research, LLC, Cooper City

33401

Metabolic Research Institute Inc., West Palm Beach

34652

Suncoast Clinical Research, New Port Richey

36608

Internal Medicine Center LLC, Mobile

37232

Vanderbilt Univeristy School of Medicine, Nashville

37411

University Diabetes and Endocrine Consultants, Chattanooga

38133

AM Diabetes and Endocrinology Center, Bartlett

40503

Kentucky Diabetes Endocrinology Center, Lexington

48154

Adult Endocrinology Consultants, P.C., Livonia

48302

Grunberger Diabetes Institute, Bloomfield Hills

50314

Iderc, P.L.C., Des Moines

59101

Billings Clinic Research Center, Billings

60012

Midwest CRC, Crystal Lake

60612

John H. Stroger Hospital of Cook County, Chicago

62711

HSHS Medical Group Diabetes Research, Springfield

65109

JCMG Clinical Research, Jefferson City

66606

Cotton O'Neil Diabetes and Endocrinology Center, Topeka

68114

Diabetes and Endocrinology Associates, Omaha

71203

The Arthritis & Diabetes Clinic Inc., Monroe

73104

University of Oklahoma Health Sciences Center-Tulsa, Oklahoma City

75230

Dallas Diabetes Endocrine Center, Dallas

78681

Texas Diabetes and Endocrinology, P.A., Round Rock

78749

Texas Diabetes and Endocrinology-Austin South, Austin

83404

Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls

84405

Advanced Research Institute, South Ogden

89128

Palm Research Center, Las Vegas

89148

Palm Research Center, Las Vegas

91342

Olive View Medical Center, Sylmar

91942

Diabetes and Endocrine Associates, La Mesa

92037

Scripps Whittier Diabetes Institute, La Jolla

92377

Inland Empire Liver Foundation, Rialto

93534

First Valley Medical Group, Lancaster

93720

Valley Endocrine, Fresno, Fresno

94520

John Muir Physician Network Clinical Research Center, Concord

94583

NorCal Endocrinology and Internal Medicine - Roseville, San Ramon

94607

Pacific Research Partners, LLC, Oakland

95661

NorCal Endocrinology and Internal Medicine - Roseville, Roseville

97210

Portland Diabetes & Endocrine Center, Portland

98003

Dr. Larry Stonesifer, Federal Way

98057

Rainier Clinical Research Center, Renton

98405

Multicare Health System, Tacoma

99208

Northside Internal Medicine, Spokane

03063

Southern New Hampshire Diabetes and Endocrinology, Nashua

02886

Sudhir Bansal M.D. Inc., Warwick

00956

Dr Altagracia Aurora Alcantara Gonzalez, Bayamón

00674

Manati Center for Clinical Research Inc, Manatí

00717

Endocrine Lipid Diabetes Research Institute, Ponce

00917

American Telemedicine Center, San Juan

00921

Martha Gomez Cuellar M.D., San Juan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Insulet Corporation

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT02561078 - An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter